

Domain Led Time Series Analysis Of Cardiovascular Disease Using Open Data – Does Reduction in Coronary Disease Increase Heart Failure Prevalence?

Alicja Jasinska-Piadlo^{1,2}, Raymond Bond², Pardis Biglarbeigi², Patricia Campbell³, D. McEneaney^{1,3}

¹ Cardiovascular Research Department, Craigavon Area Hospital, Craigavon, UK

² Faculty of Computing, Engineering & Built Environment, Ulster University, Northern Ireland, UK

³ Department of Cardiology, Craigavon Area Hospital, Craigavon, UK

Abstract

Accessing healthcare data for research purposes is lengthy and requires a data controller and ethical approval. There are, however, open data that exist in the public domain that can be freely accessed and used for research purposes. We performed a time series analysis of cardiovascular disease trends in Northern Ireland during the years 2010-2020. We accessed the Raw Disease Prevalence Data for NI from the Quality Outcomes Framework (QOF) published on the government website. Statistical analysis was performed to explore trends in prevalence for patients with coronary artery disease (CAD), heart failure (HF), and atrial fibrillation (AF). Data analysis was performed using MATLAB version R2021b. There was a significant increase in the prevalence of patients with HF and AF against a steady decrease of coronary artery disease prevalence in NI population. The prevalence of HF was higher in GP practices located more than 60 minutes drive from two primary PCI centers in NI. Our analysis shows that publicly available data have useful research value when research questions are asked by clinical experts.

(BICIS) collects data on percutaneous coronary interventions (PCI) [4]. Data on admissions of patients with HF in England and Wales are collected by the National Cardiac Audit Program (NICOR) [5]. In Scotland HF data are collected by the Information Services Division and published as an annual report - Scottish Heart Disease Statistics [6]. In Northern Ireland (NI) however there is no auditable registry collecting data on HF admissions or provision of HF secondary care. Nevertheless, there is an open access prevalence data of specific conditions in primary care published by Quality Outcome Framework (QOF) that is used to calculate payments for procedures within each clinical domain [7]. Based on available statistics, the prevalence of CAD has been decreasing in Europe over past decades [2]. We hypothesize however, that HF prevalence increases as patients are surviving to a more advanced age with access to modern evidence-based pharmacotherapy and device therapy like implantable cardiac defibrillators and cardiac resynchronization therapy. To test our hypothesis, we performed time series analysis of the trends of CAD and HF in NI based on the QOF data. We further explored the differences of HF prevalence at the regional and granular level, looking at the health and social care trusts prevalence and the prevalence at the GP practice level.

1. Introduction

Coronary artery disease (CAD) remains the leading cause of mortality in western countries [1]. In the UK, CAD affects approximately 2.6 million people [2]. Acute or chronic myocardial ischemia, a consequence of CAD, is one of the major causes for developing heart failure (HF) with reduced left ventricular ejection fraction (LVEF). HF is associated with high mortality and lengthy recurrent hospital admissions. To monitor the prevalence of HF and CAD in UK, various organizations collect data from primary and secondary care. Data on coronary events leading to myocardial infarction (MI) are routinely collected by UK-wide Myocardial Ischaemia National Audit Project (MINAP) [3]. British Cardiovascular Intervention Society

2. Materials

The QOF Register with row prevalence data was available from the Department of Health website [7]. The register runs from 31st March to 31st March of the following year between the years 2009 and 2020. The register gives the postal address of 359 GP practices in NI and includes prevalence data for the practice population. Register provides the prevalence of: coronary heart disease, heart failure, stroke, hypertension, diabetes, atrial fibrillation (AF) and other noncardiovascular conditions [7]. Since QOF began in 2004, 39 out of 359 GP practices were either closed or merged between themselves, creating bigger practices. Each GP practice in NI operates within one of 5 health and social care (HSC) trusts: Belfast, South-

Eastern, Northern, Southern and Western Trust.

3. Methods and Results

In the first instance we used data from the register to plot the prevalence of conditions of interest (Fig. 1).




Figure 1. Prevalence per 1000 population of Heart Failure (HF), coronary artery disease (CAD) and Atrial Fibrillation (AF) in NI, 2010-2020.

We observed a small increase in the prevalence of HF from 0.5% in year 2010 to just 1% in year 2020. The overall annual prevalence remained below 1% of the population. There was a clear decreasing trend of CAD prevalence, however AF prevalence has been on a steady increase since the beginning of the register. We then looked at each of 5 HSC trusts and plotted HF prevalence for each of them (Fig. 2), observing a quite rapid increase of HF prevalence since 2015.




Figure 2. Prevalence of heart failure per 1000 population in each Health and Social Care Trust in NI, years 2010-2020.

To be able to see more granular data on the HF prevalence within each GP practice, we used histogram to look for the HF prevalence distribution within practices (Figure 3). The prevalence of HF in most GP practices was between 0.5% to 1% of the practice population. This may suggest a possible under-reporting and possible under-recognition of HF given that the WHO estimates the HF prevalence at 2% [2]. We used a Chi-squared test to test if




Figure 3. Histogram of annual prevalence of heart failure in a GP practice population, expressed by percentage, Northern Ireland, years 2010-2020.

there was a statistically significant difference between the frequencies of HF in consecutive years. We used proportions of the total number of HF patients in each year to the total NI population for that year to calculate p-value as in the following equation:

$$p = (n1 + n2)/(N1 + N2); \quad (1)$$

where: p = p-value for the Chi square test
 $n1$ = number of patients with a condition in (Year 1)
 $n2$ = number of patients with a condition in the following year (Year 1) + 1
 $N1$ = total NI population in (Year 1)
 $N2$ = total NI population for the following year (Year 1) + 1

We achieved a drop in p-value (Table 1) for proportion of number of patients between year 2014 and 2015, which lead us to reject the null hypothesis and we were able to show that there was a significant increase in the proportion of patients with HF in consecutive years, resulting in an increasing trend of HF prevalence in NI. Similarly, we were able to show a decreasing trend of p-value for AF prevalence, suggesting that there was a significant increase in AF patients within the total population (Table 1). Contrary to HF and AF, there was a decreasing trend of CAD prevalence in NI which was supported statistically by applying a Chi-square test to the proportions of patients with CAD (Table 1).

Bearing in mind that in September 2012 there was a regional rollout of the 24 hour Primary Percutaneous Coronary Intervention (PPCI) service in NI, we examined HF prevalence in rural and urban areas with different travel times to PPCI. Timely access to coronary revascularization is correlated with better outcomes [8], whereas delay of revascularization in the setting of the acute coronary syndrome increases the risk of myocardial damage, which as a consequence can lead to HF. We cross checked postcodes for each GP practice with the most recent version of the

Table 1. p-value for proportions of HF patients in consecutive years.

Tax Year	p-value HF	p-value CAD	p-value AF
2010/2011	0.856	0.024	0.0000294
2011/2012	0.485	0.025	0.0000327
2012/2013	0.711	0.125	0.098357
2013/2014	0.282	0.151	0.000003
2014/2015	0.046	0.045	0.00000000995
2015/2016	0.011	0.251	09.4602e-12
2016/2017	0.001	0.062	6.8612e-13
2017/2018	0.001	0.062	0
2018/2019	0.003	0.512	0.000000000194
2019/2020	0.002	0.315	0.00000000108

National Statistics Postcode Lookup (NSPL) for the UK from February 2021 and matched it with the data from the lookup table of the 890 Super Output Areas (SOA2011) to obtain defaulted urban/rural classification for each practice and travel times to Belfast and Derry/Londonderry, where 2 PPCI centers are located. Geo data were accessed from NI Statistics and Research Agency and Office for National Statistics websites. Urban area has been defined as a settlement with a population greater than or equal to 5,000 people, whereas the rural area has a population of less than 5,000 people. There were 97 practices in rural areas and 261 in urban areas. 1 practice was allocated to the mixed rural/urban area. This practice has been excluded from the analysis.




Figure 4. Heart Failure prevalence in GP practices located in rural and urban areas, Northern Ireland, years 2010-2020.

As illustrated by Fig.4, HF prevalence in rural GP practices was higher than in urban GP practices. We then divided practices from rural and urban areas into 2 subgroups: “close” and “distant” practices. In the first subgroup, named “close”, we included all practices that were within less than 20 minutes travel to Belfast or Derry/Londonderry. In the second subgroup, named “distant”, we included all practices with a travel time greater

than 60 minutes to Belfast and Derry/Londonderry.




Figure 5. HF prevalence in rural vs urban practices, with 2 categories of GP practices: “close” practices: less than 20 minutes travel time to PPCI center and “distant” practices: travel time more than 60 minutes from PPCI center, NI, 2010 -2019.

We applied the unpaired Mann-Whitney U-test to those two subgroups. Mann-Whitney U-test examines the null hypothesis that data in x and y are samples from continuous distributions with equal medians, against the alternative that they are not. We hypothesised whether there were statistically significant differences in HF prevalence between “distant” and “close” practices regardless of the default status of the practice as rural or urban as per definition. We calculated U statistics and p-value for rural and urban practices. The statistics did not suggest to be significant, even though we observed a consistent year on year difference in the HF prevalence between rural and urban areas. This may be the shortcoming of statistical analysis.

4. Discussion

In summary, data obtained from various open sources allowed us to present trends of cardiovascular conditions for the NI population over the last decade. We were able to show that there is a significant increase in HF prevalence in NI from 2015 onward and that there is a difference in HF prevalence in urban and rural GP practices, as well as in practices located further away from PPCI centers. The QOF team published their own analyses, however they did not describe the trends that we have observed using this dataset. This supports a theory that close collaboration between clinicians and data analysts can lead to knowledge discovery from information included in health care data [9].

We had an opportunity to evaluate the dynamics of HF prevalence in different NI HSC trusts and at the GP practice level. We were not able to show, however, the factors directly influencing the increase in HF prevalence on this register. We may only speculate that this could be due to the increased awareness of HF care, as new life-saving evidence-based therapies such as sacubitril/valsartan were

introduced and as a result of a significant increase in HF education dissemination. Advancements of HF device therapy could play a role too [10]. There may be another reason for the increase in HF prevalence from year 2014 onward. This could be a result of the introduction of NI regional 24/7 revascularization service in September 2012. As shown by the prevalence of HF in practices located more than 60 minutes away from the PPCI center is higher than in closer areas, there may be some correlation. Differences in HF prevalence may be caused by timely access to specialized cardiac teams for patients from distant GP practices. This observation, however, could be only a correlation, as we can not prove a causation.

AF showed the most rapid increase in prevalence in this time series. This may be a result of intensification of active screening for AF, to which primary care physicians are encouraged to. The detection of AF carries a benefit on multiple levels. Detected and treated AF reduces the risk of stroke, which is the major cause of disability and increased costs to the economy due to lost employment years.

There are limitations to our analysis due to the quality of the available data. The QOF register represents the aggregated population information, hence it lacks detailed information on gender and age ranges of the included patients. From the clinicians' perspective this dataset is not optimal. There is a need for the high quality data gathered at the central level. Prevalence and health outcome data are needed to monitor the efficiency of the healthcare service. Well-run secondary analyses by trained health data scientists can better inform policy makers how to adopt a healthcare system to maximize patient health outcomes. The value of population-based studies has been recognized previously and led to the implementation of standard data collection sets that can measure, analyze, and improve outcomes achieved in the delivery of care of challenging groups of health conditions. We advocate for the development of automated data collection tools for the care quality improvement, outcome measure, and research purposes.

Acknowledgements

This work was supported by Public Health Agency (PHA) and Research and Development Department of Health and Social Care in Northern Ireland, UK. First author is a recipient of a Doctoral Fellowship Award (grant number EAT/5495/18).

References

- [1] Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. *Circulation* 2020;141(9):e139–e596.
- [2] Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos EA, Maggioni AP, Kazakiewicz D, May HT, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. *European Heart Journal* 2020;41(1):12–85.
- [3] Wilkinson C, Weston C, Timmis A, Quinn T, Keys A, Gale CP. The myocardial ischaemia national audit project (MINAP). *European Heart Journal Quality of Care and Clinical Outcomes* 2020;6(1):19–22.
- [4] Ludman PF. British Cardiovascular Intervention Society Registry for audit and quality assessment of percutaneous coronary interventions in the United Kingdom. *Heart* 2011; 97(16):1293–1297.
- [5] Gale CP, Weston C, Denaxas S, Cunningham, et al. Engaging with the clinical data transparency initiative: a view from the National Institute for Cardiovascular Outcomes Research (NICOR), 2012.
- [6] Scotland PH. Scottish Heart Disease Statistics-year ending 31st March 2020. URL <https://publichealthscotland.scot/publications/scottish-heart-disease-statistics/scottish-heart-disease-statistics-year-ending-31-march-2020/>.
- [7] of Health D. Raw Disease Prevalence Data, 2020. URL <https://www.health-ni.gov.uk/publications/201920-raw-disease-prevalence-trend-data-northern-ireland>.
- [8] Collet JP, Thiele H. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *European Heart Journal* 2021;42(14):1289–1367.
- [9] Ben-Assuli O, Heart T, Shlomo N, Klempfner R. Bringing big data analytics closer to practice: A methodological explanation and demonstration of classification algorithms. *Health Policy and Technology* 2019;8(1):7–13.
- [10] McDonagh TA, Metra M, Adamo M, Gardner RS, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal* 2021; 42(36):3599–3726.

Address for correspondence:

Alicja Jasinska-Piadlo
Newtownabbey, BT37 0QB, Northern Ireland, UK.
jasinska_piadlo-a@ulster.ac.uk